Tonix Pharmaceuticals Holding CORP

Tonix Pharmaceuticals announced positive minutes from a Type C FDA meeting, confirming alignment on the design for a Phase 2 field study of its TNX-4800 to prevent Lyme disease.

Tonix Pharmaceuticals Holding Corp. announced that its Chief Medical Officer, Dr. Gregory M. Sullivan, will retire effective August 20, 2026.

Tonix Pharmaceuticals announced a significant agreement with a pharmacy benefit manager, extending TONMYA coverage to approximately 9 million Medicare Part D beneficiaries starting January 1, 2027.

Tonix Pharmaceuticals has enrolled the first participant in its Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder.

Tonix Pharmaceuticals announced a new agreement with a group purchasing organization, expanding commercial coverage for its fibromyalgia drug TONMYA to approximately 52 million U.S. lives.

Tonix Pharmaceuticals announced the publication of Phase 1 clinical data for its investigational monoclonal antibody, TNX-1500, showing favorable safety and efficacy in blocking immune responses.

Tonix Pharmaceuticals reported a significantly wider net loss in Q1 2026, driven by increased R&D and commercialization costs for its new fibromyalgia drug TONMYA, alongside a going concern warning.

Tonix Pharmaceuticals reports improved net loss and strong cash position, driven by equity raises and FDA approval for its fibromyalgia drug Tonmya, slated for a November 2025 launch.

Tonix Pharmaceuticals reported a significantly reduced net loss and increased cash reserves for Q2 2025, driven by successful financing activities and progress in its drug pipeline, despite ongoing liquidity concerns.

Tonix Pharmaceuticals announces its Q1 2025 financial results, focusing on the regulatory progress of TNX-102 SL for fibromyalgia and ongoing clinical developments.

Tonix Pharmaceuticals submitted a New Drug Application for TNX-102 SL for fibromyalgia and reported a net loss of $14.2 million for the third quarter of 2024.

Tonix Pharmaceuticals reported its Q2 2024 results, including a significant net loss and asset impairments, while also expressing substantial doubt about its ability to continue as a going concern.

Tonix Pharmaceuticals launched its first internally developed FDA-approved product, TONMYA for fibromyalgia, in November 2025, amidst ongoing operating losses and a going concern warning.

Tonix Pharmaceuticals submitted an NDA for TNX-102 SL for fibromyalgia and is preparing for a potential commercial launch in Q4 2025, while also advancing its pipeline in CNS, immunology, and infectious diseases.

Tonix Pharmaceuticals' annual filing details its stock structure, clinical pipeline, and commercialization efforts, highlighting the upcoming NDA submission for Tonmya.

Bradley Saenger, Chief Financial Officer of Tonix Pharmaceuticals Holding Corp., has acquired company shares through an employee stock purchase plan.

Tonix Pharmaceuticals Director Carolyn E. Taylor reports transactions involving the acquisition and disposition of common stock.

Director Richard Stillwell purchased 5,000 shares of Tonix Pharmaceuticals Holding Corp. common stock on June 8, 2026.

Tonix Pharmaceuticals CEO Seth Lederman purchased 5,000 shares of common stock in an open market transaction.

Director Richard Newcomb Stillwell was granted 22,700 stock options under the Tonix Pharmaceuticals 2026 Stock Incentive Plan.

Director Adeoye Y. Olukotun was granted 22,700 stock options under the Tonix Pharmaceuticals 2026 Stock Incentive Plan.

Tonix Pharmaceuticals calls a May 7, 2026 virtual annual meeting to elect directors, ratify PwC, authorize reverse stock splits up to 1-for-250 over two years, and approve a 2026 Stock Incentive Plan.

Tonix Pharmaceuticals is asking shareholders to approve a reverse stock split, an amendment to its stock incentive plan, and a new employee stock purchase plan at the upcoming annual meeting.

Tonix Pharmaceuticals is asking shareholders to approve a reverse stock split and an increase in authorized shares at a special meeting on October 30, 2024, to meet Nasdaq listing requirements and for future corporate needs.

Tonix Pharmaceuticals is holding its annual meeting to vote on key proposals including a reverse stock split to regain Nasdaq compliance and repricing of outstanding warrants.

Millennium Management LLC and affiliates have filed a Schedule 13G reporting a 5.6% beneficial ownership stake in Tonix Pharmaceuticals Holding Corp.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 8.8% of Tonix Pharmaceuticals Holding Corp. common stock.

The Vanguard Group's beneficial ownership in Tonix Pharmaceuticals Holding Corp. has dropped to 0% following an internal realignment.

The Vanguard Group has reported a 5.02% beneficial ownership stake in Tonix Pharmaceuticals Holding Corp. as of December 31, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a continued 6.7% passive ownership stake in Tonix Pharmaceuticals Holding Corp. as of December 31, 2025.

Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly disclosed a 9.2% beneficial ownership stake in Tonix Pharmaceuticals Holding Corp.